局部BRAF抑制剂治疗减轻EGFR抑制剂相关皮肤毒性
EGFR抑制剂治疗受限于MAPK通路抑制引起的靶向皮肤毒性。研究者在人皮肤角质形成细胞中证实BRAF抑制剂可反常激活EGFR下游MAPK,随后开展I期临床试验,测试局部BRAF抑制剂LUT014改善EGFR抑制剂所致皮肤毒性的假说。结论为局部LUT014安全有效地改善EGFR抑制剂相关皮疹,与反常激活MAPK机制一致。
要点
- 局部LUT014在EGFR抑制剂相关皮疹患者中耐受良好且无剂量限制性毒性。
- 低、中剂量队列中初始2级皮疹的6例患者皮疹改善。
- 局部BRAF抑制剂治疗或可避免因皮肤毒性而降低EGFR抑制剂剂量。
核心结论
- 局部LUT014安全有效地改善EGFR抑制剂所致皮疹,与反常激活MAPK机制一致。
主要发现
- LUT014耐受良好,无剂量限制性毒性。
- 低剂量和中剂量队列中6例初始为2级皮疹的患者皮疹改善。
临床怎么用
- 局部BRAF抑制剂治疗可能避免因皮肤毒性而降低EGFR抑制剂剂量,局部处理该类药物主要剂量限制性皮肤毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of cancer with EGFR inhibitors is limited by on-target skin toxicities induced by inhibition of the MAPK pathway. BRAF inhibitors are known to paradoxically activate the MAPK downstream of EGFR, which we confirmed using human skin keratinocytes. We then conducted a phase I clinical trial testing the hypothesis that topical therapy with the BRAF inhibitor LUT014 could improve skin toxicities induced by EGFR inhibitors. Ten patients with metastatic colorectal cancer who had developed acneiform rash while being treated with cetuximab or panitumumab were enrolled in three cohorts. LUT014 was well tolerated, and there were no dose-limiting toxicities. The acneiform rash improved in the 6 patients who started with grade 2 rash in the low and intermediate cohorts. We conclude that topical LUT014 is safe and efficacious in improving rash from EGFR inhibitors, consistent with the mechanism of action inducting paradoxical MAPK activation. SIGNIFICANCE: BRAF inhibitor topical therapy could avoid dose reductions of EGFR inhibitors, locally treating the main dose-limiting skin toxicity of this class of agents.This article is highlighted in the In This Issue feature, p. 2113.
引用
- Lacouture ME, Wainberg ZA, Patel AB, et al. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. Cancer Discov. 2021. PMID: 33910927. doi:10.1158/2159-8290.CD-20-1847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。